What are the precautions for moboxetinib?

In clinical studies of Mobocertinib, warnings and precautions such as QTc prolongation and torsade de pointes, interstitial lung disease/pneumonitis, cardiotoxicity, diarrhea, and embryonic-fetal toxicity have emerged. Discontinue and resume at reduced dose upon recovery, or permanently discontinue based on severity.

1. QTc prolongation and torsade de pointes: Excitation can lead to life-threatening rate-corrected QT (QTc) prolongation, including fatal torsades de pointes. The doctor will assess baselineQTc and electrolytes and correct sodium, potassium, calcium, and magnesium abnormalities before starting surgery. Monitor QTc and electrolytes regularly during treatment. Frequent monitoring should be increased in patients with risk factors for QTc prolongation, such as congenital long QT syndrome, heart disease, severe renal impairment, or electrolyte abnormalities. Avoid concomitant drugs known to prolong the QTc interval. Avoid concomitant use of strong or moderate CYP3A inhibitors, which may further prolong QTc.

2. Interstitial lung disease (ILD)/pneumonitis: Mobosetinib may cause ILD/pneumonitis, which may be fatal. Monitor patients for new or worsening pulmonary symptoms suggestive of ILD/pneumonitis. Surgery should be discontinued immediately in patients with suspected ILD/pneumonitis and permanently if ILD/pneumonitis is confirmed.

3. Cardiotoxicity: Mobosetinib can cause cardiotoxicity (including reduced ejection fraction, cardiomyopathy, and congestive heart failure), leading to fatal heart failure. Patients undergoing surgical treatment also developed atrial fibrillation, ventricular tachycardia, first-degree atrioventricular block, second-degree atrioventricular block, left bundle branch block, premature supraventricular contractions, and premature ventricular contractions. Monitor cardiac function, including assessment of left ventricular ejection fraction at baseline and during treatment.

4. Diarrhea: Mobosetinib may cause diarrhea, which may be serious. In clinical studies, the median time to first onset of diarrhea was 5 u200bu200bdays, but diarrhea occurred within 24 hours after taking mobosetinib. Among the 48% of patients whose diarrhea resolved, the median time to resolution was 3 days. Diarrhea may lead to dehydration or electrolyte imbalance, with or without renal impairment. Treat diarrhea promptly. Advise patients to start an antidiarrheal medication (such as loperamide) at the first sign of diarrhea or increased bowel frequency and to increase fluid and electrolyte intake.

5. Embryo-Fetal toxicity: Based on the results of animal studies and its mechanism of action, mobosetinib can cause fetal damage when used in pregnant women. During organogenesis, maternal exposure to oral moboxetinib in pregnant rats resulted in embryonic lethality approximately 1.7 times that of human exposure, based on the area under the curve at a clinical dose of 160 mg once daily.

Inform pregnant women of potential risks to the fetus. Advise females of reproductive potential to use effective non-hormonal contraceptives during treatment and for 1 month after the last dose; recommend that men who are partners of female partners of reproductive potential use effective contraception during treatment and for 1 week after the last dose.